A Study To Find The Best Doses Of SU011248 And Gemcitabine When Given Together To Patients With Advanced Solid Tumors

Pfizer

Status and phase: Completed; Phase 1

Conditions: Solid Tumors

Treatments: Drug: SU011248; Gemcitabine

Study type: Interventional

Funder types: Industry

Identifiers

NCT00615446

A6181041

Details and patient eligibility

About

This study assesses the maximum tolerated dose, overall safety and antitumor activity of SU011248 in combination with gemcitabine in patients with advanced solid tumors

Enrollment: 44 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with diagnosis of a solid cancer which is not responsive to standard therapy or for which no standard therapy exists
• Patient has good performance status (ECOG 0 or 1)

Exclusion criteria

• Prior treatment with either gemcitabine or SU011248
• Hypertension that cannot be controlled by medications

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

44 participants in 1 patient group

A

Experimental group

Treatment:

Drug: SU011248; Gemcitabine